XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jan. 31, 2025
Jan. 31, 2024
Jan. 31, 2023
Income Statement [Abstract]      
Revenue $ 151,283 $ 148,086 $ 142,527 [1]
Cost of Revenue 98,534 96,465 94,371
Gross Profit 52,749 51,621 48,156
Costs and Expenses:      
Selling and Marketing 25,560 24,428 24,456
Research and Development 6,610 6,906 6,822
General and Administrative 15,816 11,491 11,435
Goodwill Impairment 13,403 0 0
Operating Expenses 61,389 42,825 42,713
Operating Income (Loss) (8,640) 8,796 5,443
Other Income (Expense):      
Interest Expense (3,210) (2,697) (1,678)
Gain (Loss) on Foreign Currency Transactions 335 (83) (474)
Other, net (772) 57 119
Total Other Income (Expense) (3,647) (2,723) (2,033)
Income (Loss) before Income Taxes (12,287) 6,073 3,410
Income Tax Provision 2,202 1,379 749
Net Income (Loss) $ (14,489) $ 4,694 $ 2,661
Net Income (Loss) Per Common Share-Basic $ (1.93) $ 0.63 $ 0.36
Net Income (Loss) Per Common Share-Diluted $ (1.93) $ 0.63 $ 0.36
Weighted Average Number of Common Shares Outstanding—Basic 7,509 7,415 7,307
Dilutive Effect of Common Stock Equivalents 0 [2] 81 67
Weighted Average Number of Common Shares Outstanding—Diluted 7,509 7,496 7,374
[1] Certain amounts have been reclassified to conform to the current year's presentation.
[2] For the year ended January 31, 2025, we had weighted average common stock equivalent shares outstanding of 45,908 that could potentially dilute earnings per share in future periods. These shares were excluded from the computation of diluted earnings per share because their effect would have been anti-dilutive given the net loss during the period.